NASDAQ : BCYC
Bicycle Therapeutics plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 3.82 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 267.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 256.17M |
| Enterprise Value | -200.89M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 69.99M |
| Shares Change (YoY) | +0.71% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | 39.09% |
| Float | 7.76M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.07 |
| Forward PS | 31.45 |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.09 |
| Quick Ratio | 11.75 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -793.95 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -25.24% |
| Return on Assets (ROA) | -14.46% |
| Return on Invested Capital (ROIC) | -16.85% |
| Return on Capital Employed (ROCE) | -29.47% |
| Weighted Average Cost of Capital (WACC) | 12.51% |
| Revenue Per Employee | $290,028 |
| Profits Per Employee | -$492,326 |
| Employee Count | 288 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.70M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -55.26% |
| 50-Day Moving Average | 3.83 |
| 200-Day Moving Average | 4.56 |
| Relative Strength Index (RSI) | 48.07 |
| Average Volume (20 Days) | 514,904 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.45M |
| Short Previous Month | 3.30M |
| Short % of Shares Out | 8.84% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 83.53M |
| Gross Profit | -145.56M |
| Operating Income | -154.03M |
| Pretax Income | -139.09M |
| Net Income | -141.79M |
| EBITDA | -149.42M |
| EBIT | -154.03M |
| Loss Per Share | -$2.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 469.93M |
| Total Debt | 12.86M |
| Net Cash | 457.06M |
| Net Cash Per Share | $6.53 |
| Equity (Book Value) | 505.28M |
| Book Value Per Share | 7.21 |
| Working Capital | 493.10M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -175.18M |
| Capital Expenditures | -1.86M |
| Depreciation & Amortization | 4.61M |
| Net Borrowing | -199,000 |
| Free Cash Flow | -177.04M |
| FCF Per Share | -$2.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | -174.26% |
| Operating Margin | -184.40% |
| Pretax Margin | -166.52% |
| Profit Margin | -169.75% |
| EBITDA Margin | -178.89% |
| EBIT Margin | -184.40% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.71% |
| Shareholder Yield | n/a |
| Earnings Yield | -55.57% |
| FCF Yield | -69.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.17 |
| Price Target Difference | 150.46% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -40.08% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |